Stockscreener 앱 받기
0.00
100.00%
-221.38
전일 마감가:
$221.38
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$6.96B
수익:
$302.00K
순이익/손실:
$-117.10M
주가수익비율:
0.00
EPS:
-11.13
순현금흐름:
$-129.13M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$221.42
Cidara Therapeutics Inc Stock (CDTX) Company Profile
명칭
Cidara Therapeutics Inc
전화
858-752-6170
주소
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
0.00 | 6.96B | 302.00K | -117.10M | -129.13M | -11.13 |
VRTX
Vertex Pharmaceuticals Inc
|
431.80 | 110.67B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
745.73 | 80.98B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.03 | 49.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.18 | 41.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.24 | 33.28B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-17 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-17 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-16 | 개시 | Morgan Stanley | Overweight |
| 2025-10-10 | 개시 | JP Morgan | Overweight |
| 2025-06-18 | 재개 | H.C. Wainwright | Buy |
| 2025-03-12 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-27 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-11-08 | 개시 | Guggenheim | Buy |
| 2024-08-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | 재개 | H.C. Wainwright | Buy |
| 2021-09-22 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | 개시 | Aegis Capital | Buy |
| 2019-09-04 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-07-26 | 개시 | Citigroup | Buy |
| 2017-04-21 | 개시 | Raymond James | Strong Buy |
| 2017-04-17 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Ladenburg Thalmann | Buy |
| 2017-04-11 | 재개 | Wedbush | Outperform |
| 2017-02-22 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-22 | 업그레이드 | WBB Securities | Sell → Hold |
| 2016-12-21 | 재개 | Leerink Partners | Outperform |
| 2016-12-19 | 개시 | H.C. Wainwright | Buy |
| 2016-09-23 | 다운그레이드 | WBB Securities | Hold → Sell |
| 2015-10-09 | 업그레이드 | WBB Securities | Sell → Hold |
| 2015-05-11 | 개시 | Jefferies | Buy |
| 2015-05-11 | 개시 | Leerink Partners | Outperform |
| 2015-05-11 | 개시 | Needham | Buy |
| 2015-05-11 | 개시 | Wedbush | Outperform |
| 2015-04-23 | 개시 | WBB Securities | Sell |
모두보기
Cidara Therapeutics Inc 주식(CDTX)의 최신 뉴스
Cidara Therapeutics (CDTX) Price Target Increased by 10.71% to 185.77 - MSN
Guidance Update: Is Cidara Therapeutics Inc a good ESG investmentInsider Buying & Community Verified Trade Signals - baoquankhu1.vn
Sentiment Review: Is Cidara Therapeutics Inc being accumulated by smart money2026 Fundamental Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation - MSN
Cidara Therapeutics (CDTX) Price Target Increased by 77.93% to 134.30 - MSN
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline - CNBC
Cidara Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US1717572069 - marketscreener.com
Gainers Report: Will Cidara Therapeutics Inc outperform during market ralliesNew Guidance & Proven Capital Preservation Tips - baoquankhu1.vn
Morgan Stanley Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation - MSN
Superstring Capital's New Axsome Therapeutics Position: A $6.84M Biopharma InvestmentNews and Statistics - IndexBox
Merck completes purchase of biopharma company making experimental flu drug - WFMZ.com
Cidara Therapeutics (CDTX) Price Target Increased by 24.94% to 167.79 - MSN
CDTX SEC FilingsCidara Theraptcs 10-K, 10-Q, 8-K Forms - Stock Titan
Breakout Move: Will Cidara Therapeutics Inc outperform during market rallies2026 Retail Activity & Precise Swing Trade Alerts - baoquankhu1.vn
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck - The Coloradoan
Patterns Watch: Can Cidara Therapeutics Inc sustain its profitabilityEarnings Miss & Smart Allocation Stock Tips - baoquankhu1.vn
Why Cidara Therapeutics Inc. stock could see breakout soonWeekly Market Outlook & High Accuracy Swing Trade Signals - Naître et grandir
Baron Health Care Fund adds TMO, ARQT, and ELAN; exits Cidara Therapeutics, MASI among Q4 moves - MSN
Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck - MSN
Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover - Stocktwits
Baron Health Care Fund Q4 2025 Contributors And Detractors - Seeking Alpha
Cidara Therapeutics, Inc. (CDTX) Stock Analysis: Is This Biotech Pioneer Poised for Growth? - DirectorsTalk Interviews
Cidara Therapeutics announces inclusion in the Russell 2000 and 3000 indexes - MSN
Block Trades: Is Cidara Therapeutics Inc benefiting from innovation trendsMarket Performance Report & Daily Stock Trend Watchlist - baoquankhu1.vn
Cidara Therapeutics, Inc. (CDTX) Stock Report: Navigating a Biotech Trail with a Market Cap of $6.96 Billion - DirectorsTalk Interviews
Point72 entities disclose 1.4% Cidara Therapeutics (CDTX) stake in Schedule 13G/A - Stock Titan
Can Cidara Therapeutics Inc. sustain its profitabilityJuly 2025 Highlights & Low Risk High Reward Ideas - mfd.ru
Is Cidara Therapeutics Inc. being accumulated by smart money - mfd.ru
Is Cidara Therapeutics Inc. stock dividend yield sustainableJuly 2025 Gainers & Free Expert Approved Momentum Trade Ideas - mfd.ru
How cyclical is Cidara Therapeutics Inc.’s revenue streamIPO Watch & Stepwise Trade Execution Plans - mfd.ru
Vivo Opportunity funds exit Cidara Therapeutics (CDTX) after merger completion - Stock Titan
Is Cidara Therapeutics Inc. benefiting from innovation trendsWeekly Trade Review & Weekly High Potential Stock Alerts - mfd.ru
RedChip Fintech & DATS Conference Replays Now Available Featuring Public Companies Shaping the Future of Digital Finance - USA Today
Merck Completes Tender Offer and Moves to Acquire Cidara Therapeutics - The Healthcare Technology Report.
Merck & Co., Inc. Q4 Earnings Call Highlights - MarketBeat
Portfolio Recap: How sensitive is Cidara Therapeutics Inc to inflationTrade Ideas & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Merck (MRK) Faces One-Time Charge Due to Cidara Acquisition - GuruFocus
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline - Business Wire
Aug Highlights: How sensitive is Cidara Therapeutics Inc to inflationQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn
Biotech Stocks Worth WatchingJanuary 8th - MarketBeat
Top Biotech Stocks To Watch NowJanuary 2nd - MarketBeat
Cidara Therapeutics, Inc. (CDTX) Stock Analysis: Understanding the Dynamics of a $6.96 Billion Biotech - DirectorsTalk Interviews
Is Cidara Therapeutics Inc. on track to beat earnings2025 Pullback Review & Entry and Exit Point Strategies - Mfd.ru
Published on: 2026-01-28 17:40:21 - mfd.ru
Promising Biotech Stocks To ConsiderJanuary 4th - MarketBeat
Pharma News: What is the earnings history of Cidara Therapeutics IncWeekly Risk Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Biotech Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Cidara Therapeutics, Inc. (CDTX) Stock Analysis: Navigating the Biotech Landscape with Potential Upside - DirectorsTalk Interviews
Biotech Stocks To Follow NowJanuary 5th - MarketBeat
Weekly Earnings: Is Cidara Therapeutics Inc benefiting from innovation trends2025 Key Lessons & High Conviction Trade Alerts - baoquankhu1.vn
Best Biotech Stocks To Keep An Eye OnJanuary 14th - MarketBeat
Cidara Therapeutics Inc (CDTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.29%
1.91%
자본화:
|
볼륨(24시간):